1. Home
  2. VPG vs CTNM Comparison

VPG vs CTNM Comparison

Compare VPG & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VPG

Vishay Precision Group Inc.

HOLD

Current Price

$126.19

Market Cap

552.5M

Sector

Technology

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$12.46

Market Cap

489.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
VPG
CTNM
Founded
2009
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
552.5M
489.4M
IPO Year
2010
2024

Fundamental Metrics

Financial Performance
Metric
VPG
CTNM
Price
$126.19
$12.46
Analyst Decision
Strong Buy
Buy
Analyst Count
2
4
Target Price
$53.50
$19.00
AVG Volume (30 Days)
652.6K
149.3K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.46
EPS
N/A
N/A
Revenue
$307,202,000.00
N/A
Revenue This Year
$7.21
N/A
Revenue Next Year
$6.92
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.22
N/A
52 Week Low
$25.49
$3.57
52 Week High
$136.21
$16.33

Technical Indicators

Market Signals
Indicator
VPG
CTNM
Relative Strength Index (RSI) 76.00 42.61
Support Level $32.38 $12.43
Resistance Level N/A $13.26
Average True Range (ATR) 9.99 0.70
MACD 0.85 -0.15
Stochastic Oscillator 78.55 14.94

Price Performance

Historical Comparison
VPG
CTNM

About VPG Vishay Precision Group Inc.

Vishay Precision Group Inc manufactures and markets sensors and sensor-based measurement systems, as well as specialty resistors and strain gages based on proprietary technology. The company provides precision products and solutions, many of which are designed-in by customers, specializing in the growing markets of stress, force, weight, pressure, and current measurements. The company reports in three product segments: Sensors segment, Weighing Solutions segment, and Measurement Systems segment. It has a business presence in the United States and other countries. It generates the maximum of its revenue from the United States.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: